^
    Back
    Association details:
    Biomarker:NTRK3 fusion
    Cancer:Biliary Tract Cancer
    Drug Class:Trk inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    ESMO.org
    Title:

    Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆

    Excerpt:
    NTRK inhibitors are recommended in patients with NTRK fusions who have progressed on or are intolerant to prior treatment [III, A; ESCAT score: I-C].